Veltassa Shortage: What Providers and Prescribers Need to Know in 2026

Veltassa (patiromer sorbitex calcium) is an FDA-approved potassium binder with a well-established safety and efficacy profile for managing chronic hyperkalemia in patients with CKD, heart failure, and diabetes — particularly those maintained on RAAS inhibitor therapy. Despite not being on the FDA's official drug shortage list as of 2026, prescribers and care teams continue to field patient complaints about difficulty obtaining Veltassa. This guide summarizes the access landscape, clinical decision-making frameworks, and resources to support your patients.

Current Access Status of Veltassa (2026)

Veltassa is not on the FDA drug shortage list. Vifor Pharma (the manufacturer) continues to supply the medication through its distribution network. However, several structural factors limit pharmacy-level access:

No generic: Patent expiration is expected ~2028. Without generic competition, retail cost is approximately $1,200–$1,500/month for a 30-day supply. Many pharmacies decline to stock the drug due to low turnover and cold storage requirements.

Prior authorization burden: Most commercial and Medicare Part D plans require PA for Veltassa. Common requirements include documented serum potassium levels above 5.0–5.5 mEq/L and often step therapy through older agents such as sodium polystyrene sulfonate.

Refrigeration logistics: Veltassa requires refrigerated storage at 2–8°C, limiting distribution to pharmacies equipped for cold chain management.

Formulary variability: Veltassa is on formulary for many but not all Part D and commercial plans. Some plans cover Lokelma preferentially; others cover neither agent as Tier 2. Formulary status changes annually and affects patient out-of-pocket costs significantly.

Clinical Considerations: When to Prescribe Veltassa vs. Alternatives

Veltassa and Lokelma (sodium zirconium cyclosilicate) are the two modern potassium binders available in the U.S. The clinical decision between them involves several factors:

Setting: Lokelma's 1-hour onset makes it preferred for inpatient or acute hyperkalemia management. Veltassa's once-daily maintenance dosing is well-suited for outpatient chronic management.

Sodium sensitivity: Lokelma contains sodium; clinicians report preferring Veltassa nearly 5:1 for patients with heart failure or sodium-sensitive conditions. Veltassa is sodium-free.

Magnesium monitoring: Patiromer binds magnesium as well as potassium in the colon. Hypomagnesemia was reported in 5.3% of clinical trial patients. Monitor serum magnesium at baseline and periodically during treatment; supplement as clinically indicated.

Drug interactions: Veltassa binds many oral medications in the GI tract. All oral medications should be taken at least 3 hours before or after patiromer. Key interactions include ciprofloxacin, levothyroxine, metformin, and quinidine. Counsel patients on timing carefully.

GI precautions: Veltassa is contraindicated in severe constipation, bowel obstruction, or impaction. Avoid in patients with major GI surgery or abnormal postoperative bowel motility.

Managing the Prior Authorization Process for Veltassa

PA for Veltassa can be expedited with proper documentation. Ensure your submission includes:

Serum potassium lab results (date and value)

Underlying diagnosis (CKD stage, heart failure, diabetes)

Current RAAS inhibitor therapy and clinical rationale for continuation

Documentation of step therapy attempts (if required by the plan)

Clinical note documenting why Veltassa is preferred over alternatives (e.g., sodium sensitivity for heart failure patients)

Vifor Pharma's Veltassa Konnect program offers access support services including PA assistance, benefits investigation, and specialty pharmacy referrals. Contact them at 1-844-VELTASSA (1-844-835-8277).

Patient Financial Assistance Resources

Co-pay Savings Program: Commercially insured patients may pay as low as $0/month for up to 12 months. Not available to Medicare, Medicaid, or other government-funded plan beneficiaries. Annual maximum limits apply.

Free drug program: Uninsured patients who meet financial criteria may receive Veltassa at no cost. Contact 1-844-870-7597 for eligibility.

PAN Foundation: The Patient Access Network Foundation offers financial assistance for Veltassa. Eligibility based on income. Call 1-866-316-7263.

Free 15-day starter supply: Through Veltassa Konnect, patients can receive a free 15-day supply directly while their insurance coverage is being verified.

Pharmacy Availability Tips for Your Practice

For practices that frequently prescribe Veltassa, establishing a referral relationship with a local specialty pharmacy can dramatically reduce patient access delays. Specialty pharmacies are equipped for cold chain management and often have dedicated support for prior authorization. If your patients need help finding a pharmacy with Veltassa in stock, medfinder for providers is a service that calls local pharmacies to locate medications in stock, texting results directly to patients.

Key Takeaways for Prescribers

Veltassa is not in FDA shortage but faces real-world access barriers including specialty-only stocking, high cost, and PA requirements

Monitor serum magnesium in all patients on Veltassa; supplement as needed

Instruct patients to take all other oral medications at least 3 hours before or after Veltassa

Use Veltassa Konnect for PA support, specialty pharmacy referral, and patient financial assistance

Lokelma is an appropriate alternative — particularly in hospital settings or for patients where sodium content is not a concern